Bombay High Court Rejects Sun Pharma's Bid for Injunction Against Rival Trademark 'EsiRaft'

Introduction

In a significant ruling for the pharmaceutical industry, the Bombay High Court has dismissed Sun Pharmaceutical Industries Limited's plea for an interim injunction against Meghmani Lifesciences Limited, refusing to restrain the use of the trademark "EsiRaft" for a product treating heartburn and indigestion. The single bench of Justice Sharmila U Deshmukh, in its order dated December 23, 2025, vacated an earlier ex-parte ad-interim injunction and held that "EsiRaft" does not deceptively resemble Sun Pharma's registered mark "RACIRAFT." This decision underscores the application of established trademark principles, emphasizing holistic comparison and the non-exclusivity of descriptive elements in medicinal products. The case, titled Sun Pharmaceutical Industries Limited v. Meghmani Lifesciences Limited and Another (IA (L) No. 9484/2025 in Commercial IP (L) No. 353/2025), highlights the challenges in claiming monopoly over composite marks in a sector where products often share common ingredients and indications.

The dispute centers on oral syrups containing identical molecules—Sodium Alginate, Sodium Bicarbonate, and Calcium Carbonate—marketed for the same ailments. Sun Pharma, a global leader in pharmaceuticals, argued infringement and passing off, citing visual, phonetic, and structural similarities, including packaging color schemes. Meghmani, a Gujarat-based firm, defended its mark as bona fide, pointing to the generic nature of "RAFT" and distinct prefixes. This ruling comes at a time when intellectual property battles in India's pharma sector are intensifying, with sales figures underscoring the commercial stakes: Sun Pharma reported turnovers of ₹11.85 crore in 2022-23 and ₹24.49 crore in 2023-24 for "RACIRAFT," while Meghmani's "EsiRaft" achieved ₹89 lakhs from July 2024 to March 2025.

Case Background

Sun Pharmaceutical Industries Limited, the plaintiff, adopted the trademark "RACIRAFT" in January 2022 for its oral suspension syrup aimed at relieving heartburn and indigestion. The mark, described as an arbitrary coined term combining a misspelling of "racy" (suggesting zest) with "RAFT" (evoking foam formation from sodium alginate), was registered under Class 5 of the Trade Marks Act, 1999, on January 17, 2022. The product quickly gained traction, reflecting Sun Pharma's substantial investment in branding and marketing.

Meghmani Lifesciences Limited, the first defendant, entered the market in July 2024 with "EsiRaft," a similar syrup produced by the second defendant, a manufacturer previously engaged by Sun Pharma under an agreement prohibiting identical or similar marks. Meghmani applied for registration of "EsiRaft" (or "ESIRAFT") on March 21, 2024, on a proposed-to-use basis, explaining "ESI" as standing for "Enhanced System Improvement" from a patient perspective or "Esophageal Symptom Index" related to the ailment. The products' identical composition and therapeutic use fueled the conflict, with Sun Pharma discovering the rival mark in February 2025 and filing the suit in March 2025.

The legal questions at the heart of the case were twofold: (1) Whether "EsiRaft" infringes "RACIRAFT" under Section 29 of the Trade Marks Act, 1999, by being deceptively similar as defined in Section 2(1)(h)—i.e., so nearly resembling as to likely deceive or cause confusion; and (2) Whether Meghmani's actions constitute passing off, misrepresenting its goods as those of Sun Pharma. An ex-parte ad-interim injunction was granted on April 7, 2025, restraining Meghmani's use, but this was challenged via an oral application for vacation under Order 39 Rule 4 of the Code of Civil Procedure, 1908. The interim application proceeded to final disposal by consent on December 9, 2025, with the judgment pronounced on December 23, 2025.

This timeline reflects the fast-paced nature of IP litigation in commercial courts, where preliminary relief can significantly impact market dynamics. The Bombay High Court's Ordinary Original Civil Jurisdiction handled the matter, given Mumbai's role as a hub for pharmaceutical headquarters.

Arguments Presented

Sun Pharma's contentions focused on establishing a prima facie case of infringement and passing off, emphasizing the prior use and goodwill of "RACIRAFT." Learned counsel Mr. Hiren Kamod argued that the marks are visually, structurally, aurally, and phonetically similar, particularly in the pharmaceutical context where even slight confusion could endanger public health. They highlighted the identical ailments treated, shared molecules, and Meghmani's use of a two-color combination (e.g., distinct colors for prefix and suffix) mirroring Sun Pharma's packaging. Sales figures were tendered to prove reputation, and dishonest adoption was alleged due to the second defendant's prior manufacturing tie-up with Sun Pharma, which barred similar marks.

Mr. Kamod invoked the anti-dissection rule, urging holistic comparison from an average consumer's imperfect recollection viewpoint. He stressed greater scrutiny for medicinal products per Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd. (2001) 4 SCC 73, arguing that "Esi" could be mispronounced as "Aci," akin to "Raci." The plaintiff's reply to Meghmani's trademark examination report was cited to estop the defendant from varying its pronunciation claims (e.g., emphasizing "si" diphthong vs. "Easy"). Precedents like Boots Co. PLC v. Registrar of Trade Marks (2002) 2 Mh LJ 834 and Lupin Ltd. v. Eris Lifesciences Pvt. Ltd. (2015 SCC OnLine Bom 6807) supported claims of phonetic similarity in pharma marks. Delay in suit filing was justified as vigilant protection, with no acquiescence.

Meghmani, represented by Mr. Ashutosh Kane, countered that no exclusivity exists over "RAFT," a generic, descriptive term common in the trade for foam-inducing sodium alginate-based antacids—evidenced by 30+ third-party products using it with two-color schemes. Prefixes "RACI" (pronounced "RAY-see") and "ESI" ("Easy" or "ESY") were asserted as visually, structurally, and phonetically distinct, with the first syllable being dominant. Bona fide adoption was defended via "ESI"'s medical connotations, and the common manufacturer link was dismissed as post-adoption. The trademark registry's examination report cited "ESIRAFT" and "EASYRAFT" but not "RACIRAFT," indicating no conflict.

Mr. Kane produced physical bottles and photographs to demonstrate trade commonality, arguing against monopoly on color schemes given Sun Pharma's word-mark registration. He distinguished precedents like Cadila by noting prefix dominance and relied on J.R. Kapoor v. Micronix India (1994 Supp (3) SCC 215) and F. Hoffmann-La Roche & Co. Ltd. v. Geoffrey Manners & Co. Pvt. Ltd. (1969) 2 SCC 716 for holistic assessment favoring dissimilarity. Delay and laches were raised, as use began in July 2024, with Sun Pharma's awareness claimed only in February 2025 despite sales of 97,754 bottles.

In rejoinder, Sun Pharma reiterated Cadila 's "slightest possibility" standard for pharma cases, denying color claims extended beyond depiction manner.

Legal Analysis

The court's reasoning applied foundational principles under the Trade Marks Act, 1999, centering on Section 2(1)(h)'s definition of deceptive similarity. Justice Deshmukh emphasized judging marks "by the eye as well as the ear," per Cadila Health Care (supra), without jettisoning phonetic analysis despite visual differences. The anti-dissection rule mandated whole-mark comparison, considering average consumer perspective, imperfect recollection, and confusion likelihood—principles reiterated from Encore Electronics Ltd. v. Anchor Electronics (2007 SCC OnLine Bom 147).

Visually, "RACIRAFT" (all caps) differed from "EsiRaft" (mixed case: capital E, small si, capital R, small aft), rendering structural dissimilarity. The two-color scheme, while similar, was deemed common in the trade for antacids, insufficient alone for infringement, as photographs suggested extensive use (though full proof awaited trial). Phonetically, opening syllables diverged: "RAY-cee" vs. "Ee-see" or "Easy," with no mispronunciation risk, as vowels "E" and "A" sound distinct. The court drew from F. Hoffmann-La Roche (supra), prioritizing uncommon elements over generic suffixes like "vit" or here "RAFT," confirmed as descriptive of sodium alginate's foaming property—providing a plausible defense per the ex-parte order.

Precedents were analyzed judiciously: Cadila urged caution in pharma but required actual resemblance, absent here; Boots and Medley Laboratories v. Alkem Laboratories (2002) 3 Mh LJ 546 found similarity in closer phonetic pairs (e.g., Crofen-Brufen), unlike this case. Defendant's citations like Johann A. Wulfing v. Chemical Industrial (AIR 1984 Bom 281) reinforced suffix non-dominance. The registry's non-citation of "RACIRAFT" bolstered no-confusion finding.

On passing off, Cadila factors (nature of marks, goods similarity, purchaser class) were weighed, but absent resembleness, misrepresentation failed. Packaging differences (get-up, labels) further distanced the case. Dishonest adoption was rejected, accepting "ESI"'s explanation as cogent for medicinal naming. Sun Pharma's proprietorship was upheld against "RACI" commonality challenges, deeming it an impermissible validity attack without formal counterclaim.

This analysis distinguishes descriptive generics from arbitrary marks, clarifying that shared elements in identical-use products do not imply infringement without overall deception.

Key Observations

The judgment features several pivotal excerpts illuminating the court's rationale:

1. "Applying the well settled principles which governs the field while assessing the rival marks as regards the anti-dissection rule, view point of an average consumer with imperfect recollection, holistic comparison, the likelihood of confusion etc., in my view, the competing marks are prima facie visually and phonetically dissimilar and will not create any confusion in the minds of the consumers." This encapsulates the holistic test's application.

2. "The word ‘RAFT’ is an indicator of the product’s molecule properties, which even as per the ex-parte ad interim order, will amount to plausible defence for adoption of the mark." Highlighting the descriptive nature precluding monopoly.

3. "The well settled principles for assessing the deceptive similarity lays emphasis on visual appearance as well as the phonetic similarity i.e. that the marks have to be judged by the eye as well as the ear." Quoting core statutory interpretation from Cadila .

4. "In so far as phonetic similarity is concerned... The opening syllables of the two competing marks are completely different and normally the opening syllables are rarely mispronounced." Addressing pronunciation specifics.

5. "There is no material on record to persuade this Court to accept that the Defendant No 1 portrayed its product intentionally or unintentionally as that of the Plaintiff." Dismissing passing off absent evidence.

These observations, drawn verbatim, underscore the judgment's fidelity to precedent while tailoring to facts.

Court's Decision

The Bombay High Court unequivocally dismissed the interim application, holding Sun Pharma failed to establish a prima facie case of trademark infringement or passing off. The order vacated the April 7, 2025, ex-parte injunction, permitting Meghmani to continue using "EsiRaft" since July 2024. Ad-interim relief was extended one week post-upload for transition, but no further restraints were imposed.

Practically, this allows Meghmani to market freely, potentially boosting its ₹23 lakhs monthly sales amid competition. For Sun Pharma, it means pursuing trial on merits, possibly challenging validity, but without preliminary leverage. Broader implications affirm that descriptive suffixes like "RAFT"—tied to product efficacy—cannot support exclusivity, even in pharma where confusion risks are heightened. This may embolden innovators using medical abbreviations, provided prefixes differ and adoption is bona fide.

Future cases could see stricter scrutiny of composite marks, reinforcing Cadila 's balance: protecting goodwill without stifling competition in essential medicines. IP practitioners must now emphasize overall impression over isolated elements, potentially reducing frivolous injunctions but heightening evidentiary burdens on generics. In India's burgeoning ₹50,000 crore antacid market, this ruling promotes fair play, ensuring consumers access diverse options without deception fears. As pharma IP disputes rise—over 500 annually per recent reports—this decision sets a precedent for nuanced, evidence-based assessments, influencing licensing, manufacturing agreements, and registry examinations.